Rotavirus vaccine safety profile: A 15-year post-marketing surveillance in France

被引：0
|
作者：
Jonville-Bera, A. P. [1 ]
Michot, J. [2 ]
Micallef, J. [3 ]
Grandvuillemin, A. [4 ]
Vial, T. [5 ]
机构：
[1] CHU Tours, CRPV Ctr, Tours, France
[2] CRPV St Antoine, AP HP, Paris, France
[3] CRPV Marseille, AP HM, Marseille, France
[4] CHU Dijon, CRPV Bourgogne, Dijon, France
[5] Hospices Civils Lyon, CRPV Lyon, Lyon, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2023年 / 37卷
关键词：
adverse drug reaction; rotavirus vaccine; safety profile;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
CO-057
引用
收藏
页码：41 / 42
页数：2
相关论文
共 50 条
  • [1] Post-marketing safety surveillance of the rotavirus vaccine in India
    Kang, Gagandeep
    Lakhkar, Anand
    Bhamare, Chetanraj
    Dharmadhikari, Abhijeet
    Narwadkar, Jyoti
    Kanujia, Arti
    Desai, Sajjad
    Gunale, Bhagwat
    Poonawalla, Cyrus S.
    Kulkarni, Prasad S.
    [J]. VACCINE: X, 2023, 15
  • [2] A Post-Marketing Surveillance Program for Pentavalent Rotavirus Vaccine
    Loughlin, Jeanne
    Florence, Wang
    Eng, P. Mona
    Mast, T. Christopher
    Seeger, John D.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S27 - S27
  • [3] Fluvoxamine: Safety profile in extensive post-marketing surveillance
    Buchberger, R
    Wagner, W
    [J]. PHARMACOPSYCHIATRY, 2002, 35 (03) : 101 - 108
  • [4] Reactogenicity and safety of the human rotavirus vaccine, Rotarix™ in The Philippines, Sri Lanka, and India A post-marketing surveillance study
    Bravo, Lulu
    Chitkara, Amarjeet
    Liu, Aixue
    Choudhury, Jaydeep
    Kumar, Kishore
    Berezo, Lennie Rose
    Cimafranca, Leonard Raymund
    Chatterjee, Pallab
    Garg, Pankaj
    Siriwardena, Prassana
    Bernardo, Rommel
    Mehta, Shailesh
    Balasubramanian, Sundaram
    Karkada, Naveen
    Han, Htay Htay
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (08) : 2276 - 2283
  • [5] Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine
    Tavares-Da-Silva, Fernanda
    Co, Maribel Miranda
    Dessart, Christophe
    Herve, Caroline
    Lopez-Fauqued, Marta
    Mahaux, Olivia
    Van Holle, Lionel
    Stegmann, Jens-Ulrich
    [J]. VACCINE, 2020, 38 (18) : 3489 - 3500
  • [6] Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
    Fernanda Tavares-Da-Silva
    Olivia Mahaux
    Lionel Van Holle
    François Haguinet
    Harry Seifert
    Jens-Ulrich Stegmann
    [J]. Drug Safety, 2020, 43 : 1223 - 1234
  • [7] Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
    Tavares-Da-Silva, Fernanda
    Mahaux, Olivia
    Van Holle, Lionel
    Haguinet, Francois
    Seifert, Harry
    Stegmann, Jens-Ulrich
    [J]. DRUG SAFETY, 2020, 43 (12) : 1223 - 1234
  • [8] Post-marketing device safety surveillance
    Vidi, Venkatesan D.
    Matheny, Michael E.
    Resnic, Frederic S.
    [J]. CONTEMPORARY CLINICAL TRIALS, 2011, 32 (03) : 307 - 308
  • [9] Post-marketing surveillance of celecoxib safety: a 12-year follow-up study in France
    Chenaf, C.
    Andorra, A.
    Parry, E.
    Authier, N.
    Zenut, M.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 74 - 74
  • [10] Post-marketing surveillance of ROACTEMRA® (tocilizumab) safety: a six-year follow-up in France
    Chenaf, C.
    Andorra, A.
    Parry, E.
    Faidi, S.
    Laudet, M.
    Authier, N.
    Zenut, M.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 50 - 50
12345